Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation

Am J Cardiol. 2015 Nov 1;116(9):1368-73. doi: 10.1016/j.amjcard.2015.07.055. Epub 2015 Aug 14.

Abstract

The CHADS2 score is considered a reliable predictor of stroke/thromboembolism risk in patients with atrial fibrillation (AF). However, thromboembolism can occasionally occur even in patients with AF with low CHADS2 score (CHADS2 score = 0 or 1). To investigate the incidence and predictors of left atrial appendage (LAA) thrombus (LAAT) formation in patients with AF, we studied consecutive 543 Japanese patients with AF who underwent transesophageal echocardiography before pulmonary vein isolation from 2008 to 2012. All patients were treated with anticoagulation therapy with warfarin, and their clinical and echocardiographic characteristics were evaluated. LAATs were observed in 35 (6.4%) of 543 patients, and the prevalence was clearly correlated with the patient's CHADS2 scores. Of 338 patients with low CHADS2 score, LAATs were observed in 7 patients (2.1%). By multivariate analysis, increased left atrial volume (≥50 ml), decreased ejection fraction (<56%), and increased brain natriuretic peptide level (>75 pg/ml) were significantly associated with increased prevalence of LAATs, even in patients with low CHADS2 score. Accordingly, we proposed a new scoring system to predict LAAT (left atrial volume ≥50 ml: score 2; ejection fraction <56%: score 1; brain natriuretic peptide >75 pg/ml: score 1). Patients with a score ≥2 have a greater risk of LAAT, whereas all patients with score ≤1 have no LAATs. Our scoring system is useful for evaluation of the risk of LAAT in patients with AF even with low CHADS2 score.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Atrial Appendage / diagnostic imaging*
  • Atrial Appendage / surgery
  • Atrial Fibrillation / complications*
  • Biomarkers / blood
  • Body Mass Index
  • Catheter Ablation / methods
  • Echocardiography, Transesophageal*
  • Female
  • Humans
  • Incidence
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood
  • Predictive Value of Tests
  • Prevalence
  • Pulmonary Veins* / surgery
  • Risk Assessment
  • Risk Factors
  • Sensitivity and Specificity
  • Thromboembolism / diagnosis
  • Thromboembolism / epidemiology*
  • Thromboembolism / etiology*
  • Thromboembolism / surgery
  • Treatment Outcome

Substances

  • Biomarkers
  • Natriuretic Peptide, Brain